{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:26:51Z","timestamp":1788672411385,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T00:00:00Z","timestamp":1276214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10067-010-1500-9","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T19:20:30Z","timestamp":1276197630000},"page":"1093-1098","source":"Crossref","is-referenced-by-count":20,"title":["When should we use parenteral methotrexate?"],"prefix":"10.1007","volume":"29","author":[{"given":"Hayley","family":"Mainman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McClaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Heycock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadivelu","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","volume":"37","author":"M Weinblatt","year":"1994","unstructured":"Weinblatt M, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC et al (1994) Methotrexate in rheumatoid arthritis: a five year prospective multicenter study. Arthritis Rheum 37:1492\u20131498","journal-title":"Arthritis Rheum"},{"key":"1500_CR2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.1780400533","volume":"40","author":"JM Kremer","year":"1997","unstructured":"Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3\u00a0years. Arthritis Rheum 40:984\u2013985","journal-title":"Arthritis Rheum"},{"key":"1500_CR3","first-page":"1631","volume":"29","author":"D Aletaha","year":"2002","unstructured":"Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 29:1631\u20131638","journal-title":"J Rheumatol"},{"key":"1500_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","volume":"44","author":"AJ Kinder","year":"2005","unstructured":"Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44:61\u201366","journal-title":"Rheumatology"},{"key":"1500_CR5","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.2008.100834","volume":"67","author":"DE Furst","year":"2008","unstructured":"Furst DE, Keystone EC, Kirkham B, Fleischman R, Mease P, Breedveld FC et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 67:ii2\u2013iii25","journal-title":"Ann Rheum Dis"},{"key":"1500_CR6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","volume":"46","author":"American College of Rheumatology","year":"2002","unstructured":"American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328\u2013346","journal-title":"Arthritis Rheum"},{"key":"1500_CR7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","volume":"41","author":"D Aletaha","year":"2002","unstructured":"Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 41:1367\u20131374","journal-title":"Rheumatology"},{"key":"1500_CR8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/41.6.658","volume":"41","author":"AE Ede van","year":"2002","unstructured":"van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ (2002) Homocysteine and folate status in methotrexate treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658\u2013665","journal-title":"Rheumatology (Oxford)"},{"key":"1500_CR9","first-page":"481","volume":"33","author":"M Hoekstra","year":"2006","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2006) Splitting high-dose oral methotrexate improves bioavalability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33:481\u2013485","journal-title":"J Rheumatol"},{"key":"1500_CR10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2006.100263","volume":"56","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kremer JR et al (2007) Obesity increases oesophageal acid exposure. Gut 56:749\u2013755","journal-title":"Gut"},{"key":"1500_CR11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","volume":"50","author":"CM Lambert","year":"2004","unstructured":"Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364\u2013371","journal-title":"Arthritis Rheum"},{"key":"1500_CR12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, Kastner P, Flaxenburg P, Wahrisch J, Hanke P, Demary W et al (2008) Comparison of the clinical efficacy and safety of subcutaneous methotrexate in patients with active rheumatoid arthritis: results of a six month multicenter randomized double blind controlled phase IV trial. Arthritis Rheum 58:73\u201381","journal-title":"Arthritis Rheum"},{"key":"1500_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","volume":"36","author":"JM Kremer","year":"1997","unstructured":"Kremer JM, Hamilton RA (1997) Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol 36:86\u201390","journal-title":"Brit J Rheumatol"},{"key":"1500_CR14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/rheumatology\/kem230","volume":"47","author":"K Collins","year":"2008","unstructured":"Collins K, Aspey H, Todd A, Rynne M, Saravanan V, Kelly CA (2008) Methotrexate pneumonitis precipitated by switching from oral to subcutaneous administration. Rheumatology 47:109\u2013110","journal-title":"Rheumatology"},{"key":"1500_CR15","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31:645\u2013648","journal-title":"J Rheumatol"},{"key":"1500_CR16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"1500_CR17","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H Dongen van","year":"2007","unstructured":"van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424\u20131432","journal-title":"Arthritis Rheum"},{"key":"1500_CR18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","volume":"62","author":"M Hoekstra","year":"2003","unstructured":"Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423\u2013426","journal-title":"Ann Rheum Dis"},{"key":"1500_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43:22\u201329","journal-title":"Arthritis Rheum"},{"key":"1500_CR20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JA Wessels","year":"2007","unstructured":"Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765\u20131775","journal-title":"Arthritis Rheum"},{"key":"1500_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/ard.2008.088237","volume":"58","author":"SL Hider","year":"2009","unstructured":"Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons DPM (2009) Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 58:57\u201362","journal-title":"Ann Rheum Dis"},{"key":"1500_CR22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ije\/dyg108","volume":"32","author":"L Murray","year":"2003","unstructured":"Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P et al (2003) Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol 32:645\u2013650","journal-title":"Int J Epidemiol"},{"key":"1500_CR23","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/art.1780391203","volume":"39","author":"BN Cronstein","year":"1996","unstructured":"Cronstein BN (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 39:1951\u20131960","journal-title":"Arthritis Rheum"},{"key":"1500_CR24","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.21762","volume":"54","author":"P Ranganathan","year":"2006","unstructured":"Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366\u20131377","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"1500_CR25","first-page":"376","volume":"46","author":"LA Criswell","year":"2002","unstructured":"Criswell LA, Lum RF, Turner KN, Peden EA, Means GD, Derry MJ et al (2002) The HLA-DRB1 shared epitope as a predictor of response to treatment of RA with methotrexate and etanercept. Arthritis Rheum 46(Suppl):376","journal-title":"Arthritis Rheum"},{"key":"1500_CR26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/rheumatology\/ken513","volume":"48","author":"YC Lee","year":"2009","unstructured":"Lee YC, Cui J, Costenbader JH, Shadick NA, Weinblatt ME, Karlson EW (2009) Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 48:613\u2013617","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1500-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1500-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T16:54:43Z","timestamp":1591376083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1500-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1500-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}